AngioDynamics Inc (ANGO) SEC filings

ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 12/306% below fair value

$12.42+0.35 (+2.90%)

Close on Nov 11, 2026Market cap $522.32MP/E –Yield –

SEC filings

40 of AngioDynamics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Aug 31, 2026	Oct 8, 2026	SEC EDGAR
Proxy statement	DEF 14A	Nov 17, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Oct 8, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Oct 2, 2026	Oct 8, 2026	SEC EDGAR
Annual report, amended	10-K/A	May 31, 2026	Sep 29, 2026	SEC EDGAR
Annual report, amended	10-K/A	May 31, 2026	Sep 29, 2026	SEC EDGAR
Annual report	10-K	May 31, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	Jul 14, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Quarterly report	10-Q	Feb 28, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Apr 2, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Jan 30, 2026	Feb 3, 2026	SEC EDGAR
Current report	8-K	Jan 14, 2026	Jan 14, 2026	SEC EDGAR
Quarterly report	10-Q	Nov 30, 2025	Jan 6, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 6, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Aug 31, 2025	Oct 2, 2025	SEC EDGAR
Current report	8-K	Oct 2, 2025	Oct 2, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 31, 2025	Sep 25, 2025	SEC EDGAR
Annual report	10-K	May 31, 2025	Jul 18, 2025	SEC EDGAR
Current report	8-K	Jul 15, 2025	Jul 15, 2025	SEC EDGAR
Current report	8-K	May 28, 2025	May 28, 2025	SEC EDGAR
Quarterly report	10-Q	Feb 28, 2025	Apr 2, 2025	SEC EDGAR
Current report	8-K	Apr 2, 2025	Apr 2, 2025	SEC EDGAR
Current report	8-K	Apr 2, 2025	Apr 2, 2025	SEC EDGAR
Current report	8-K	Jan 16, 2025	Jan 16, 2025	SEC EDGAR
Quarterly report	10-Q	Nov 30, 2024	Jan 8, 2025	SEC EDGAR
Current report	8-K	Jan 8, 2025	Jan 8, 2025	SEC EDGAR
Current report	8-K	Jan 8, 2025	Jan 8, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 15, 2024	SEC EDGAR
Quarterly report	10-Q	Aug 31, 2024	Oct 3, 2024	SEC EDGAR
Current report	8-K	Oct 3, 2024	Oct 3, 2024	SEC EDGAR
Proxy statement	DEF 14A	May 31, 2024	Sep 26, 2024	SEC EDGAR
Annual report	10-K	May 31, 2024	Jul 25, 2024	SEC EDGAR
Current report	8-K	Jul 16, 2024	Jul 16, 2024	SEC EDGAR
Current report	8-K	Jul 16, 2024	Jul 16, 2024	SEC EDGAR
Quarterly report	10-Q	Feb 29, 2024	Apr 9, 2024	SEC EDGAR
Current report	8-K	Apr 4, 2024	Apr 4, 2024	SEC EDGAR
Current report	8-K	Mar 31, 2024	Apr 1, 2024	SEC EDGAR
Current report	8-K	Feb 8, 2024	Feb 13, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in AngioDynamics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ANGO.

Compare: ANGO vs LMAT · ANGO vs AORT · ANGO vs DCTH · ANGO vs ATRC · ANGO vs ARAY

Revenue growth8.2% · median 13.8%

Gross margin55.7% · median 72.0%

Operating margin-11.2% · median 2.9%

Net margin-10.1% · median 2.5%

Company	Revenue	Growth
ATRC	$589.80M	+13.8%
AORT	$481.88M	+14.0%
ARAY	$394.53M	-12.5%
ANGO	$325.38M	+8.2%
LMAT	$269.36M	+11.8%
DCTH	$109.96M	+38.1%

Company

Next earnings (est.): Jan 5, 2027, before open
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: May 31
Employees: 632
Held by institutions: 91.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1275187

Advertisement
300 × 250

See a number that looks wrong?